Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics

Basit Öğe Kaydı
dc.authoridAnderson, Jr, Larry D./0000-0002-6531-9595
dc.authoridSalomo, Morten/0000-0002-1660-1607
dc.authoridSchjesvold, Fredrik/0000-0003-1096-0569
dc.authoridmoreau, philippe/0000-0003-1780-8746
dc.authorscopusid34571744900
dc.authorscopusid24401832100
dc.authorscopusid57219346143
dc.authorscopusid14527450700
dc.authorscopusid36112856100
dc.authorscopusid8283554700
dc.authorscopusid23089719200
dc.authorwosidAnderson, Jr, Larry D./H-8363-2019
dc.contributor.authorRichardson, Paul G.
dc.contributor.authorSchjesvold, Fredrik
dc.contributor.authorWeisel, Katja
dc.contributor.authorMoreau, Philippe
dc.contributor.authorAnderson, Larry D., Jr.
dc.contributor.authorWhite, Darrell
dc.contributor.authorRodriguez-Otero, Paula
dc.date.accessioned2023-01-12T20:01:51Z
dc.date.available2023-01-12T20:01:51Z
dc.date.issued2022
dc.departmentN/A/Departmenten_US
dc.description.abstractObjective We evaluated the efficacy and safety of pomalidomide, bortezomib, and dexamethasone (PVd) vs bortezomib and dexamethasone (Vd) by age, renal function, and high-risk cytogenetic abnormalities in lenalidomide-pretreated patients with multiple myeloma at first relapse. Methods OPTIMISMM was a phase 3, multicenter, open-label, randomized study (NCT01734928; N = 559). The primary endpoint was progression-free survival (PFS). Results Overall, 226 patients had received one prior line of therapy. PVd significantly prolonged PFS vs Vd in patients aged <= 65 years (median, 22.0 vs 13.1 months; P = .0258) and >65 years (median, 17.6 vs 9.9 months; P = .0369). Median PFS in patients with renal impairment (RI; creatinine clearance <60 mL/min) was 15.1 months with PVd vs 9.5 months with Vd (hazard ratio [HR], 0.67 [95% CI, 0.34-1.34]). In patients without RI, median PFS was 22.0 vs 13.1 months (HR, 0.45 [95% CI, 0.27-0.76]). In patients with high-risk cytogenetics, median PFS was 14.7 vs 9.9 months (HR, 0.39 [95% CI, 0.13-1.17]). PVd significantly improved overall response rate vs Vd in all subgroups. The safety profile of PVd was consistent with previous reports. Conclusions These findings confirmed the benefits of PVd at first relapse, including in patients with poor prognostic factors.en_US
dc.description.sponsorshipBristol-Myers Squibben_US
dc.description.sponsorshipBristol-Myers Squibben_US
dc.identifier.doi10.1111/ejh.13706
dc.identifier.endpage83en_US
dc.identifier.issn0902-4441
dc.identifier.issn1600-0609
dc.identifier.issue1en_US
dc.identifier.pmid34496096en_US
dc.identifier.scopus2-s2.0-85115264782en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage73en_US
dc.identifier.urihttps://doi.org/10.1111/ejh.13706
dc.identifier.urihttps://hdl.handle.net/11454/77524
dc.identifier.volume108en_US
dc.identifier.wosWOS:000697742400001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofEuropean Journal of Haematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectageden_US
dc.subjectchromosome aberrationsen_US
dc.subjectmultiple myelomaen_US
dc.subjectpomalidomideen_US
dc.subjectrenal insufficiencyen_US
dc.subjectRelapsed/Refractory Multiple-Myelomaen_US
dc.subjectLow-Dose Dexamethasoneen_US
dc.subjectHigh-Risk Cytogeneticsen_US
dc.subjectCombinationen_US
dc.titlePomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristicsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu